Maximum Dose of Abilify Maintena
The maximum recommended dose of Abilify Maintena is 400 mg administered monthly as a single intramuscular injection 1.
Standard Dosing
The FDA-approved dosing for Abilify Maintena is straightforward:
- Recommended dose: 400 mg monthly (intramuscular injection in deltoid or gluteal muscle)
- Dose reduction option: 300 mg monthly - this is reserved for patients experiencing adverse reactions, not as a higher dose option 1
Special Population: CYP2D6 Poor Metabolizers
For patients who are known CYP2D6 poor metabolizers, the dosing is actually lower, not higher:
- Starting and maintenance dose: 300 mg monthly 1
This is because poor metabolizers cannot adequately break down aripiprazole, leading to higher plasma concentrations at standard doses.
Clinical Context
The 400 mg monthly dose represents the ceiling for this formulation. Clinical studies demonstrate that 90.1% of patients (1,296/1,439) initiated on 400 mg required no dose changes, indicating this dose is both the starting point and the therapeutic maximum for most patients 2. The mean aripiprazole plasma concentrations achieved with 400 mg monthly (93-112 ng/mL) fall within the established therapeutic window of 94.0-534.0 ng/mL 2.
Extended Interval Formulation
A newer 2-month formulation exists (Ari2M/Abilify Asimtufii) with a 960 mg dose given every 2 months, which is bioequivalent to the 400 mg monthly formulation 3, 4. However, this is not a "higher dose" but rather the same total monthly exposure delivered less frequently.
Important Caveats
- There is no approved dose higher than 400 mg monthly for the standard monthly formulation
- Doses should not be increased beyond 400 mg monthly to achieve better efficacy
- If inadequate response occurs at 400 mg, consider switching medications rather than exceeding the maximum dose
- The 300 mg dose is a reduction for tolerability, not a step in upward titration